With 81785.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.23 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.9397 whereas the lowest price it dropped to was $0.8925. The 52-week range on MTNB shows that it touched its highest point at $9.60 and its lowest point at $0.47 during that stretch. It currently has a 1-year price target of $30.00. Beta for the stock currently stands at 1.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MTNB was down-trending over the past week, with a drop of -13.47%, but this was up by 18.25% over a month. Three-month performance surged to 57.88% while six-month performance rose 58.43%. The stock lost -88.72% in the past year, while it has gained 76.45% so far this year.
Float and Shares Shorts:
At present, 5.09 million MTNB shares are outstanding with a float of 4.56 million shares on hand for trading. On 2025-05-30, short shares totaled 62393.0, which was 123.00000499999999 higher than short shares on 1745971200. In addition to Mr. Jerome D. Jabbour J.D. as the firm’s Co-Founder, Chairman, CEO and President, Mr. Keith A. Kucinski CPA, M.B.A. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.05899 of MTNB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, MTNB reported revenue of $0.0 and operating income of -$1946000.0. The EBITDA in the recently reported quarter was -$2112000.0 and diluted EPS was -$0.33.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$4.06 being high and -$4.06 being low. For MTNB, this leads to a yearly average estimate of -$4.06.
